Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.78), Zacks reports. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%.
Arcturus Therapeutics Stock Performance
Shares of ARCT stock traded down $0.08 during trading hours on Thursday, reaching $15.97. The company had a trading volume of 296,381 shares, compared to its average volume of 412,633. Arcturus Therapeutics has a 12-month low of $14.30 and a 12-month high of $45.00. The company has a market capitalization of $432.58 million, a price-to-earnings ratio of -7.19 and a beta of 2.62. The stock has a fifty day moving average of $17.02 and a 200-day moving average of $18.66.
Analyst Ratings Changes
ARCT has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research report on Friday, February 14th. BTIG Research initiated coverage on shares of Arcturus Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $41.00 target price for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $65.00.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
Read More
- Five stocks we like better than Arcturus Therapeutics
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?
- What is the FTSE 100 index?
- Super Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?
- What is the S&P 500 and How It is Distinct from Other Indexes
- Taiwan Semi’s $100 Billion Investment: Fate of the Chipmakers
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
